Principal Financial Group Inc Krystal Biotech, Inc. Transaction History

Principal Financial Group Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$174.7 - $213.66 $653,902 - $799,729	-3,743 Reduced 3.03%	119,726 $21.8 Million
Q2 2024 Jul 29, 2024	BUY	$153.12 - $183.64 $18 Million - $21.6 Million	117,510 Added 1971.98%	123,469 $22.7 Million
Q1 2024 Apr 29, 2024	BUY	$108.01 - $179.35 $17,281 - $28,696	160 Added 2.76%	5,959 $1.06 Million
Q4 2023 Feb 07, 2024	BUY	$96.0 - $128.29 $2,976 - $3,976	31 Added 0.54%	5,799 $719,000
Q3 2023 Nov 02, 2023	SELL	$108.51 - $130.22 $13,563 - $16,277	-125 Reduced 2.12%	5,768 $669,000
Q2 2023 Aug 07, 2023	SELL	$78.48 - $130.32 $18,835 - $31,276	-240 Reduced 3.91%	5,893 $691,000
Q1 2023 May 09, 2023	BUY	$72.39 - $84.27 $34,747 - $40,449	480 Added 8.49%	6,133 $491,000
Q4 2022 Feb 09, 2023	BUY	$63.14 - $79.9 $16,668 - $21,093	264 Added 4.9%	5,653 $447,000
Q3 2022 Nov 09, 2022	BUY	$64.85 - $82.4 $48,572 - $61,717	749 Added 16.14%	5,389 $376,000
Q2 2022 Aug 10, 2022	BUY	$48.93 - $73.47 $227,035 - $340,900	4,640 New	4,640 $305,000
Q4 2021 Feb 09, 2022	SELL	$39.81 - $88.24 $173,412 - $384,373	-4,356 Closed	0 $0
Q3 2021 Nov 09, 2021	SELL	$52.01 - $71.77 $36,615 - $50,526	-704 Reduced 13.91%	4,356 $227,000
Q2 2021 Aug 10, 2021	SELL	$62.14 - $81.82 $156,779 - $206,431	-2,523 Reduced 33.27%	5,060 $344,000
Q1 2021 May 10, 2021	BUY	$59.42 - $85.46 $772 - $1,110	13 Added 0.17%	7,583 $585,000
Q4 2020 Feb 08, 2021	BUY	$40.64 - $61.38 $307,644 - $464,646	7,570 New	7,570 $454,000

306

24.2M

483K

364K

Ticker KRYS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,664,300
Market Cap $3.97B
Description
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.